Statistics
Publications
18
Citations
1K
H-Index
14
Active since
2010
Laurence Fayadat‐Dilman is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in antibody characterization, pharmacy, and antibody engineering.
Publications per year
2010–2024
18
18
Predicting Antibody Developability Profiles Through Early Stage Discovery Screening
Marc Bailly, Carl Mieczkowski, Veronica Juan et al. · mAbs · 2020 · 223 citations · Full text
In Vivo Imaging of the Programmed Death Ligand 1 by <sup>18</sup>F PET
D. E. González Trotter, Xiangjun Meng, Paul McQuade et al. · Journal of Nuclear Medicine · 2017 · 100 citations
Medicine, Nuclear Medicine, Oncology +17
1–5 of 18